Successful treatment of meticillin-resistant Staphylococcus aureus (MRSA) aortic prosthetic valve endocarditis with prolonged high-dose daptomycin plus ceftaroline therapy

Cunha, Burke A.; Gran, Arthur

doi:10.1016/j.ijantimicag.2015.04.006

Cited by 13 publications

(9 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…One case reported success of combination salvage therapy with ceftaroline and daptomycin for MRSA prosthetic valve IE after failure of multiple other agents [26]. The patient had persistent bacteremia despite courses of vancomycin, quinupristin/dalfopristin, and linezolid.…”

Section: Resultsmentioning

confidence: 99%

Ceftaroline for Severe Methicillin-Resistant Staphylococcus aureus Infections: A Systematic Review

Cosimi

Beik

Kubiak³

et al. 2017

Open Forum Infectious Diseases

View full text Add to dashboard Cite

Ceftaroline is approved by the Food and Drug Administration for acute bacterial skin and skin-structure infections and community-acquired bacterial pneumonia, including cases with concurrent bacteremia. Use for serious methicillin-resistant Staphylococcus aureus (MRSA) infections has risen for a multitude of reasons. The aim of this article is to review the literature evaluating clinical outcomes and safety of ceftaroline prescribed for serious MRSA infections. We conducted a literature search in Ovid (Medline) and PubMed for reputable case reports, clinical trials, and reviews focusing on the use of ceftaroline for treatment of MRSA infections. Twenty-two manuscripts published between 2010 and 2016 met inclusion criteria. Mean clinical cure was 74% across 379 patients treated with ceftaroline for severe MRSA infections. Toxicities were infrequent. Ceftaroline treatment resulted in clinical and microbiologic cure for severe MRSA infections. Close monitoring of hematological parameters is necessary with prolonged courses of ceftaroline.

show abstract

Section: Resultsmentioning

confidence: 99%

Ceftaroline for Severe Methicillin-Resistant Staphylococcus aureus Infections: A Systematic Review

Cosimi

Beik

Kubiak³

et al. 2017

Open Forum Infectious Diseases

View full text Add to dashboard Cite

show abstract

“…There are several case reports of ceftaroline being used to successfully treat refractory or drug-resistant MRSA PVE, either alone (168) or in combination therapy (169). In one case report, the efficacy and tolerability of ceftaroline were demonstrated in one patient with osteomyelitis and endocarditis caused by an MRSA strain that was not susceptible to daptomycin (170).…”

Section: Alternative Therapiesmentioning

confidence: 99%

“…In one case report, the efficacy and tolerability of ceftaroline were demonstrated in one patient with osteomyelitis and endocarditis caused by an MRSA strain that was not susceptible to daptomycin (170). A patient with MRSA aortic PVE was also cured with prolonged high-dose daptomycin plus ceftaroline after other therapeutic failures (169).…”

Section: Alternative Therapiesmentioning

confidence: 99%

Methicillin-Resistant Staphylococcus aureus Prosthetic Valve Endocarditis: Pathophysiology, Epidemiology, Clinical Presentation, Diagnosis, and Management

et al. 2019

View full text Add to dashboard Cite

SUMMARY Staphylococcus aureus prosthetic valve endocarditis (PVE) remains among the most morbid bacterial infections, with mortality estimates ranging from 40% to 80%. The proportion of PVE cases due to methicillin-resistant Staphylococcus aureus (MRSA) has grown in recent decades, to account for more than 15% of cases of S. aureus PVE and 6% of all cases of PVE. Because no large studies or clinical trials for PVE have been published, most guidelines on the diagnosis and management of MRSA PVE rely upon expert opinion and data from animal models or related conditions (e.g., coagulase-negative Staphylococcus infection). We performed a review of the literature on MRSA PVE to summarize data on pathogenic mechanisms and updates in epidemiology and therapeutic management and to inform diagnostic strategies and priority areas where additional clinical and laboratory data will be particularly useful to guide therapy. Major updates discussed in this review include novel diagnostics, indications for surgical management, the utility of aminoglycosides in medical therapy, and a review of newer antistaphylococcal agents used for the management of MRSA PVE.

show abstract

“…11,12,14 High-dose daptomycin in combination with ceftaroline for 6 weeks successfully treated patients with aortic PVE caused by MRSA. 28 Daptomycin was mostly used as a second-line treatment; however, the clinical success rate was higher when daptomycin was used as a first-line treatment. Seaton et al 29 reported higher clinical success rates with first-line as compared with second-line daptomycin treatment in patients with MRSA infections.…”

Section: Discussionmentioning

confidence: 99%

Effectiveness and safety of daptomycin in patients with infective endocarditis undergoing heart valve replacement: a subgroup analysis from real-world data

Guleri

Utili

Dohmen

et al. 2017

Therapeutic Advances in Infection

View full text Add to dashboard Cite

show abstract

Successful treatment of meticillin-resistant Staphylococcus aureus (MRSA) aortic prosthetic valve endocarditis with prolonged high-dose daptomycin plus ceftaroline therapy

Cited by 13 publications

References 5 publications

Ceftaroline for Severe Methicillin-Resistant Staphylococcus aureus Infections: A Systematic Review

Ceftaroline for Severe Methicillin-Resistant Staphylococcus aureus Infections: A Systematic Review

Methicillin-Resistant Staphylococcus aureus Prosthetic Valve Endocarditis: Pathophysiology, Epidemiology, Clinical Presentation, Diagnosis, and Management

Effectiveness and safety of daptomycin in patients with infective endocarditis undergoing heart valve replacement: a subgroup analysis from real-world data

Contact Info

Product

Resources

About